Immune Deficiency Foundation Launches New Website Dedicated to Those Living with Chronic Granulomatous Disease
TOWSON, Md., Feb. 3, 2015 /PRNewswire/ -- The Immune Deficiency Foundation (IDF) announces the launch of LivingwithCGD.org, a new website dedicated to those living with Chronic Granulomatous Disease (CGD). The site will provide the latest news and information regarding diagnosis and treatment and serve as a platform to connect individuals and families living with CGD.
CGD is a rare type of primary immunodeficiency disease (PI) in which one group of the body's white blood cells, called neutrophils, fail to make the hydrogen peroxide, bleach and other chemicals needed to fight bacterial and fungal infections. CGD affects an estimated 1,200 people in the U.S. and approximately 25,000 people worldwide.
IDF, the national patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with PI, developed LivingwithCGD.org to raise awareness of this rare disease and be a resource for the community. IDF is the largest national voice for individuals with PI, a group of more than 240 rare, chronic disorders.
"We are delighted to expand our advocacy and education efforts for the CGD community by developing this site," said Marcia Boyle, IDF President & Founder, "We hope that individuals and families with CGD will see this as a vital resource and a place for them to come together to learn the latest news and information, gain encouragement and advocate on behalf of our community."
IDF launches the site at a pivotal time for CGD, as more treatment options are available today, enabling patients to lead healthier and more active lives.
Horizon Pharma plc, the manufacturer of a medication used by patients with CGD, generously sponsored the site.
"We are pleased to support IDF and LivingwithCGD.org to help raise awareness of CGD and educate the community," said Brian Andersen, vice president and general manager, orphan business unit, Horizon Pharma plc. "We are dedicated to partnering with IDF to help improve the quality of life for individuals and families affected by CGD."
IDF will host its first two-day CGD Symposium at the IDF 2015 National Conference in New Orleans June 25-27. For information, visit the site at LivingwithCGD.org.
About The Immune Deficiency Foundation
The Immune Deficiency Foundation (IDF), founded in 1980, is the national non-profit patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education and research. To learn more about IDF, visit www.primaryimmune.org, or call 800.296.4433.
About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.
SOURCE Immune Deficiency Foundation
Share this article